Pepgen reports first quarter 2022 financial results and recent corporate developments

Boston, june 16, 2022 (globe newswire) -- pepgen inc. (“pepgen”), a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapies with the goal of transforming the treatment of severe neuromuscular and neurological diseases, today reported financial results for the first quarter ended march 31, 2022.
PEPG Ratings Summary
PEPG Quant Ranking